Our business model contemplates the development, patenting and exploitation of our technology and product leads by means of exclusive licenses or joint ventures with Pharmaceutical, Veterinary, Diagnostics and Biotechnology companies.
Based on a validated and flexible technology platform, which is the result of nearly a decade of dedicated research, Algenex is currently in the phase of developing and perfecting a new generation of innovative vaccines and diagnostics, which combine the properties of speed of development, safety in production and handling and a greatly reduced manufacturing cost.
Our short to medium-term development is focused in three main areas:
Optimization of recombinant protein production technology.
Improvement of baculovirus based vectors.
Development of a line of vaccines and diagnostics as well as new approaches to pharmaceutical, diagnostic and vaccine products.
